Invasive pulmonary aspergillosis and pulmonary cryptococcosis really coexist in immunocompromised host

J Infect. 2006 Aug;53(2):e55-8. doi: 10.1016/j.jinf.2005.10.017. Epub 2005 Dec 1.

Abstract

Fungal infections develop slowly in immunocompetent patients and rarely a severe disease, however, they progress rapidly and usually prove fatal in immunocompromised patients. Early diagnosis and treatment of fungal infections is essential to survival of immunocompromised patients. We report a 33-year-old woman with systemic lupus erythematosus undergoing immunotherapy infected with combined invasive pulmonary aspergillosis and pulmonary cryptococcosis diagnosed by video-assisted thoracic surgery lung biopsy and she was successfully treated as a result of early diagnosis and treatment.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Aspergillosis / complications*
  • Aspergillosis / drug therapy
  • Cryptococcosis / complications*
  • Cryptococcosis / drug therapy
  • Female
  • Fluconazole / therapeutic use
  • Humans
  • Immunocompromised Host*
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases, Fungal / complications*
  • Lung Diseases, Fungal / drug therapy
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy

Substances

  • Antifungal Agents
  • Immunosuppressive Agents
  • Amphotericin B
  • Fluconazole